Thankamma Ajithkumar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Thankamma Ajithkumar has a total of 215 co-authors. Here are the top co-authors by number of shared publications:
Hm Hatcher
6 shared publicationsBeate Timmermann
Department of Particle Therapy, University Hospital Essen, West German Proton Therapy Centre Essen, West German Cancer Center, Essen, Germany
5 shared publicationsGail Horan
Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
5 shared publicationsLaetitia Padovani
Aix-Marseille University, Oncology Radiotherapy Department, CRCM Inserm, UMR1068, CNRS UMR7258, AMU UM105, Genome Instability and Carcinogenesis, APHM, Marseille, France
4 shared publicationsYasmin Lassen-Ramshad
Danish Centre for Particle Therapy, Aarhus, Denmark
4 shared publicationsBarbara Rombi
Proton Therapy Center, Santa Chiara Hospital, Trento, Italy
3 shared publications
Latest Publications
- Open Access
- 3 June 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (9) , 2234-2247
Final report of the SIOP-CNS-GCT II protocol for germinoma: Omitting radiotherapy boost is safe in localized disease in complete remission after chemotherapy
Background: For localized germinoma, whole-ventricular radiotherapy (WVRT) is standard-of-care in Europe; 24 Gray (Gy) with 16 Gy boost following chemotherapy. The SIOP-CNS-GCT-II trial aimed to examine the effect of response-adapted radiotherapy on patient outcome. Methods: Patients with localized germinoma received 4 courses of “carboPEI” chemotherapy, then 24 Gy WVRT if in complete remission (CR), with an additional 16 Gy tumor boost if residual disease was present. Metastatic cases received 24 Gy craniospinal radiotherapy (CSRT) with 16 Gy boost to all sites. Results: Between 2012 and 2018, 227 fully-staged germinoma patients were treated according to protocol. Five-year event-free (EFS) and overall survival (OS) for 166 localized germinoma were 0.94 ± 0.02 and 0.98 ± 0.01, respectively. Sixty-five of 166 (39.2%) were in CR after chemotherapy, of whom 64/65 received 24 Gy WVRT, only 2 of whom (2/64; 3.1%) relapsed. Of 90/166 patients in partial remission (PR) after chemotherapy, 88/90 received 24 Gy WVRT + 16 Gy; 2 relapsed (2/88; 2.3%). Of the 11 remaining patients, 8 had stable disease (SD) after chemotherapy; 7/8 received 24 Gy WVRT + 16 Gy boost and 1 received 24 Gy WVRT + 30 Gy boost because of a teratoma component; none relapsed. Three remaining patients with progressive disease (PD) during chemotherapy had variable treatments, due to differing histologies and disease spread; 1 relapsed. Five-year EFS and OS for 61 metastatic germinoma were 0.98 ± 0.02 and 1.00 ± 0.00, respectively, with 55/61 (90.2%) in CR and 5/61 (11.5%) in PR after 24 Gy CSRT + 16 Gy; 1 relapsed. Conclusions: Response-adapted radiotherapy for localized germinoma led to excellent survival outcomes. Further treatment de-escalation should be considered in future strategies to reduce treatment burden and late effects.
- 3 June 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (9) , 2234-2247
Open AccessFinal report of the SIOP-CNS-GCT II protocol for germinoma: Omitting radiotherapy boost is safe in localized disease in complete remission after chemotherapy
Background: For localized germinoma, whole-ventricular radiotherapy (WVRT) is standard-of-care in Europe; 24 Gray (Gy) with 16 Gy boost following chemotherapy. The SIOP-CNS-GCT-II trial aimed to examine the effect of response-adapted radiotherapy on patient outcome. Methods: Patients with localized germinoma received 4 courses of “carboPEI” chemotherapy, then 24 Gy WVRT if in complete remission (CR), with an additional 16 Gy tumor boost if residual disease was present. Metastatic cases received 24 Gy craniospinal radiotherapy (CSRT) with 16 Gy boost to all sites. Results: Between 2012 and 2018, 227 fully-staged germinoma patients were treated according to protocol. Five-year event-free (EFS) and overall survival (OS) for 166 localized germinoma were 0.94 ± 0.02 and 0.98 ± 0.01, respectively. Sixty-five of 166 (39.2%) were in CR after chemotherapy, of whom 64/65 received 24 Gy WVRT, only 2 of whom (2/64; 3.1%) relapsed. Of 90/166 patients in partial remission (PR) after chemotherapy, 88/90 received 24 Gy WVRT + 16 Gy; 2 relapsed (2/88; 2.3%). Of the 11 remaining patients, 8 had stable disease (SD) after chemotherapy; 7/8 received 24 Gy WVRT + 16 Gy boost and 1 received 24 Gy WVRT + 30 Gy boost because of a teratoma component; none relapsed. Three remaining patients with progressive disease (PD) during chemotherapy had variable treatments, due to differing histologies and disease spread; 1 relapsed. Five-year EFS and OS for 61 metastatic germinoma were 0.98 ± 0.02 and 1.00 ± 0.00, respectively, with 55/61 (90.2%) in CR and 5/61 (11.5%) in PR after 24 Gy CSRT + 16 Gy; 1 relapsed. Conclusions: Response-adapted radiotherapy for localized germinoma led to excellent survival outcomes. Further treatment de-escalation should be considered in future strategies to reduce treatment burden and late effects.
- 29 March 2025
- Published by Springer Nature
- p. 371-394
Paediatric and Teenage and Young Adult Tumours
- Open Access
- 8 March 2023
- Published by Cambridge University Press (CUP) in Journal of Radiotherapy in Practice
- Vol. 22, e89
Can the use of knowledge-based planning systems improve stereotactic radiotherapy planning? A systematic review
Introduction: This study aimed to systematically review the literature to synthesise and summarise whether using knowledge-based planning (KBP) can improve the planning of stereotactic radiotherapy treatments.Methods: A systematic literature search was carried out using Medline, Scopus and Cochrane databases to evaluate the use of KBP planning in stereotactic radiotherapy. Three hundred twenty-five potential studies were identified and screened to find 25 relevant studies.Results: Twenty-five studies met the inclusion criteria. Where a commercial KBP was used, 72.7% of studies reported a quality improvement, and 45.5% reported a reduction in planning time. There is evidence that when used as a quality control tool, KBP can highlight stereotactic plans that need revision. In studies that use KBP as the starting point for radiotherapy planning optimisation, the radiotherapy plans generated are typically equal to or superior to those planned manually.Conclusions: There is evidence that KBP has the potential to improve the quality and speed of stereotactic radiotherapy planning. Further research is required to accurately quantify such systems’ quality improvements and time savings. Notably, there has been little research into their use for prostate, spinal or liver stereotactic radiotherapy, and research in these areas would be desirable. It is recommended that future studies use the ICRU 91 level 2 reporting format and that blinded physician review could add a qualitative assessment of KBP system performance.
- 8 March 2023
- Published by Cambridge University Press (CUP) in Journal of Radiotherapy in Practice
- Vol. 22, e89
Open AccessCan the use of knowledge-based planning systems improve stereotactic radiotherapy planning? A systematic review
Introduction: This study aimed to systematically review the literature to synthesise and summarise whether using knowledge-based planning (KBP) can improve the planning of stereotactic radiotherapy treatments.Methods: A systematic literature search was carried out using Medline, Scopus and Cochrane databases to evaluate the use of KBP planning in stereotactic radiotherapy. Three hundred twenty-five potential studies were identified and screened to find 25 relevant studies.Results: Twenty-five studies met the inclusion criteria. Where a commercial KBP was used, 72.7% of studies reported a quality improvement, and 45.5% reported a reduction in planning time. There is evidence that when used as a quality control tool, KBP can highlight stereotactic plans that need revision. In studies that use KBP as the starting point for radiotherapy planning optimisation, the radiotherapy plans generated are typically equal to or superior to those planned manually.Conclusions: There is evidence that KBP has the potential to improve the quality and speed of stereotactic radiotherapy planning. Further research is required to accurately quantify such systems’ quality improvements and time savings. Notably, there has been little research into their use for prostate, spinal or liver stereotactic radiotherapy, and research in these areas would be desirable. It is recommended that future studies use the ICRU 91 level 2 reporting format and that blinded physician review could add a qualitative assessment of KBP system performance.
- 4 November 2022
- Published by Elsevier in Clinical Oncology
- Vol. 34, e16
Hypofractionated radiotherapy for pancreatic cancer
- 4 November 2022
- Published by Elsevier in Clinical Oncology
- Vol. 34, e16
Hypofractionated radiotherapy for pancreatic cancer
- Open Access
- 1 September 2020
- Published by Elsevier in Clinical Medicine
- Vol. 20 (5) , e191-e195
Clinical presentation and outcomes of solitary plasmacytoma in a tertiary hospital in the UK
Solitary plasmacytoma is a rare localised neoplasm of monoclonal plasma cells. The standard treatment involves radical radiotherapy; however, a significant proportion of patients subsequently develop multiple myeloma. In this study, we evaluate the outcomes of solitary plasmacytoma in a retrospective cohort of patients treated in a single tertiary centre. The case records of plasmacytoma patients treated in a 15-year period were analysed and retrospectively followed up from the date of diagnosis. Thirty-four cases met the inclusion criteria; 27 (79%) solitary plasmacytoma of bone (SBP) and 7 (21%) extramedullary plasmacytoma (EMP). The thoracic vertebrae were the commonest sites for SBP while EMP occurred most frequently in the upper airway. Pain and spinal cord compression were the most frequent symptoms. A paraprotein was detectable in 18 (53%) patients. Over a median follow-up of 48 months, 13 (38%) developed multiple myeloma. The 5- and 10-year survival rates were 80% and 56%, respectively; median progression-free survival was 77 months. Four patients (12%) developed a second malignancy. Progression to multiple myeloma remains a formidable challenge in the management of solitary plasmacytoma, hence adjunct therapies are needed.
- 1 September 2020
- Published by Elsevier in Clinical Medicine
- Vol. 20 (5) , e191-e195
Open AccessClinical presentation and outcomes of solitary plasmacytoma in a tertiary hospital in the UK
Solitary plasmacytoma is a rare localised neoplasm of monoclonal plasma cells. The standard treatment involves radical radiotherapy; however, a significant proportion of patients subsequently develop multiple myeloma. In this study, we evaluate the outcomes of solitary plasmacytoma in a retrospective cohort of patients treated in a single tertiary centre. The case records of plasmacytoma patients treated in a 15-year period were analysed and retrospectively followed up from the date of diagnosis. Thirty-four cases met the inclusion criteria; 27 (79%) solitary plasmacytoma of bone (SBP) and 7 (21%) extramedullary plasmacytoma (EMP). The thoracic vertebrae were the commonest sites for SBP while EMP occurred most frequently in the upper airway. Pain and spinal cord compression were the most frequent symptoms. A paraprotein was detectable in 18 (53%) patients. Over a median follow-up of 48 months, 13 (38%) developed multiple myeloma. The 5- and 10-year survival rates were 80% and 56%, respectively; median progression-free survival was 77 months. Four patients (12%) developed a second malignancy. Progression to multiple myeloma remains a formidable challenge in the management of solitary plasmacytoma, hence adjunct therapies are needed.
- 13 September 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (4) , 31-32
Role of radiotherapy for extracranial germ cell tumours: A re-visit
- 13 September 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (4) , 31-32
Role of radiotherapy for extracranial germ cell tumours: A re-visit